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Abstract
AIM: Recent studies suggested that cyclooxygenase-2
(COX-2) enhances tumor angiogenesis via upregulation
of vascular endothelial growth factor (VEGF). Although
COX-2 expression has been demonstrated in hepatocellular
carcinoma (HCC), the significance of COX-2 in progression
of HCC remains unclear. This study evaluated the clinico-
pathological correlation of COX-2 level and its relationship
with VEGF level in HCC.
METHODS: Fresh tumor tissues were obtained from 100
patients who underwent resection of HCC. COX-2 protein
expression was examined by immunohistochemistry, and
quantitatively by an enzyme immunometric assay (EIA)
of tumor cytosolic COX-2 levels. Tumor cytosolic VEGF
levels were measured by an ELISA.
RESULTS: Immunostaining showed expression of COX-2
in tumor cells. Tumor cytosolic COX-2 levels correlated
with VEGF levels (r = 0.469, P<0.001). Correlation with
clinicopathological features showed significantly higher
tumor cytosolic COX-2 levels in the presence of multiple
tumors (P = 0.027), venous invasion (P = 0.030),
microsatellite lesions (P = 0.037) and advanced tumor
stage (P = 0.008). Higher tumor cytosolic COX-2 levels
were associated with worse patient survival.
CONCLUSION: This study shows that elevated tumor
COX-2 levels correlate with elevated VEGF levels and
invasiveness in HCC, suggesting that COX-2 plays a significant
role in the progression of HCC.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Cyclooxygenase (COX) is a membrane-bound enzyme
responsible for the oxidation of arachidonic acid to
prostaglandin G2 and its subsequent reduction to prostaglandin
H2[1,2]. Cyclooxygenase is expressed in at least two different
isoforms, a constitutively expressed form, COX-1, and an
inducible form, COX-2[2-4]. COX-1 is expressed in many
normal tissues and is involved in a number of  homeostatic
body functions, such as hemostasis, vasodilatation in renal
vessels, and cytoprotection of the gastric mucosa[4]. The
expression of  COX-2 is induced by various stimuli, such as
growth factors and cytokines, and is involved in chronic
inflammatory pathologies such as inflammatory bowel
disease[4,5]. COX-2 was recently found to have angiogenic
property[6,7]. This has attracted strong research interest in its
significance in human cancers because of the potential use
of  COX-2 inhibitors in cancer therapy[8,9]. Recent studies have
highlighted the relevance of  COX-2 in human carcinogenesis
and cancer progression. There is evidence that COX-2
enhances the angiogenic and metastatic potential of tumor
cells[10]. Studies in human colorectal cancer[7], head and neck
cancer[11], endometrial cancer[12] and breast cancer[13] suggested
that COX-2 is involved in the angiogenesis and progression
of  these cancers. Recent data have indicated that COX-2
stimulates angiogenesis through induction of vascular
endothelial growth factor (VEGF)[12,14,15]. VEGF is known
to be a specific stimulator of endothelial cell proliferation
in many human cancers[16], and it is the most potent angiogenic
factor for tumor angiogenesis.
Hepatocellular carcinoma (HCC) is a highly malignant
tumor characterized by active neovascularization[17].
Angiogenesis plays a significant role in the aggressiveness
of HCC[18,19]. Previous studies from our group have revealed
a significant association between VEGF expression and
invasiveness of HCC[20,21]. Recently, a few studies have
demonstrated the expression of  COX-2 in HCC[22-26]. Koga
et al[22], first reported the expression of  COX-2 protein in
HCC, and they found increased expression of  COX-2
by immunohistochemistry in well-differentiated HCCs
compared with less-differentiated HCCs or histologically
normal liver. The authors suggested that COX-2 might play
a role in the early stages of hepatocarcinogenesis, but not
in the advanced stages of tumor progression. Kondo et al[23],
also reported a similar relationship between COX-2
expression and differentiated HCC. In addition, they found
a significant correlation between COX-2 expression and
active inflammation in the noncancerous liver. A similar
finding in the noncancerous liver was reported by Morinaga
et al[24], who otherwise found no correlation between COX-
2 mRNA expression and clinicopathological features in HCC.
A more recent study of  COX-2 expression in HCC caused
by hepatitis B virus (HBV) revealed that COX-2 expression
correlated with VEGF expression and microvessel density
in HCC[26]. However, the role of  COX-2 in tumor progression
of  HCC is unclear. Hence, we performed a study to evaluate
the relationship between tumor COX-2 expression and
clinicopathological features of HCC.
MATERIALS AND METHODS
Patients and samples
Fresh tumor tissues and adjacent noncancerous liver tissues
were obtained immediately from the resected specimens
of 100 HCC patients who underwent hepatectomy at the
Department of Surgery of the University of Hong Kong
at Queen Mary Hospital, Hong Kong between January 1,
1998 and December 31, 2001. Fresh tissue samples were
snap-frozen in liquid nitrogen and stored at -80 ℃ for
analysis of  cytosolic COX-2 and VEGF protein levels. For
immunohistochemistry, tissue samples were fixed in 10%
neutral buffered formalin and embedded in paraffin. Paraffin
sections of  normal liver from 10 living liver donors for
transplantation were also collected for immunohistochemical
study of  COX-2 expression as controls. All clinical samples
were collected with informed consent. The study was approved
by the Institutional Review Board of our institution.
Clinicopathological data
Tissue sections (4-m thick) were deparaffinized in xylene,
rehydrated in graded alcohol solution, and stained with
hematoxylin and eosin solution. Histological examination
of  resected specimens was performed by a pathologist who
was blinded to the COX-2 and VEGF expression results.
Tumor differentiation was classified into three types according
to the criteria proposed by the Liver Cancer Study Group
of Japan: well-, moderately-, and poorly-differentiated[27].
Tumors were staged by using the International Union Against
Cancer pathologic Tumor-Node-Metastasis (pTNM)
classification[28]. Histological evidence of cirrhosis in the
adjacent noncancerous livers was examined, and the adjacent
noncancerous livers were classified into those with active and
those without active inflammation according to the presence
of lymphocytic piecemeal necrosis with lobular confluent
necrosis as previously described[29]. All patients were regularly
followed in a HCC clinic and all clinicopathological and follow-
up data were collected prospectively in a computerized
database.
Immunohistochemical study of COX-2 expression
Tumor and adjacent noncancerous liver sections were
deparaffinized and rehydrated by standard procedures of
histology. Slides were then immersed in 3% hydrogen
peroxide for 15 min at 22 ℃ to quench endogenous peroxidase
activity. The slides were then microwaved in 10 mmol/L
citrate buffer (pH6.0) for 10 min for antigen retrieval.
After washing the slides in phosphate buffer saline for
10 min at 4 ℃, the specimens were preblocked for 10 min
at room temperature in biotin blocking reagent (DAKO,
Produktionsvej, Denmark). The biotin solution was washed
off with phosphate buffer saline thrice before application
of the first antibody. Then the slides were incubated overnight
with mouse antihuman COX-2 monoclonal antibody (dilution,
1:100; Cayman Chemical, Ann Arbor, MI) at 4 ℃. After
three washes in phosphate buffer saline, the sections were
incubated with rabbit biotinylated antimouse immunoglobulin
G (Zymed Lab Inc., San Francisco, CA) for 60 min at 37 ℃,
and then incubated with streptavidin-biotin complex/
horseradish peroxidase (DAKO, Produktionsvej) at room
temperature for 30 min. The slides were stained with 3,3’-
diaminobenzine tetrahydrochloride/hydrogen peroxide
solution and counterstained with hematoxylin after washing
with phosphate buffer saline. COX-2 staining was compared
with the corresponding tissue slide from the same patient
without primary antibody as negative control. Staining
of  COX-2 was defined as negative when there was
undetectable or minimal (less than 10% of the tumor
cells or hepatocytes) staining for COX-2; and positive when
>10% of the tumor cells or hepatocytes were stained for
COX-2.
Measurement of cytosolic COX-2 and VEGF levels in tumor
and adjacent noncancerous liver tissues
Cytosol was obtained by sonication of tumor and adjacent
noncancerous liver tissues. In brief, frozen tissues were
sonicated in four volumes of  RIPA buffer (25 mmol/L
Tris, pH7.4, 0.15 mol/L KCl, 1% NP-40, 5 mmol/L EDTA,
0.5% sodium deoxycholate, 0.1% SDS). Sonication was
performed for five cycles of  30-s bursts at 1-min intervals
on ice. The supernatant was collected after 5 min of
centrifugation at 15 000 g at 4 ℃ and assayed for the COX-2
and VEGF protein levels immediately. The total protein
concentration in the supernatants was measured using Bio-
Rad total protein assay (Bradford, Hercules, CA). Measurement
of  COX-2 and VEGF levels in the tissue cytosol was
performed by two separate investigators who were not aware
of the results of each other or the clinicopathological data
of the patients.
The COX-2 protein level in tissue cytosol was determined
by using a commercial enzyme immunometric assay (EIA)
kit (Assay Designs, Inc., Ann Arbor, MI). The procedure
of the EIA provided by the manual was followed. Briefly,
100 µL of  recombinant human COX-2 standard and test
samples were pipetted into a microtiter plate coated with
monoclonal antibody specific for human COX-2, and then
incubated for 1 h at 37 ℃. After washing off any unbound
substances, 100 µL of a rabbit polyclonal antibody to human
COX-2 conjugated with the enzyme horseradish peroxidase
was added to the wells to sandwich the COX-2. Finally,
substrate solution was added for color development. The
intensity of color developed, which was in proportion to
the quantity of  COX-2 bound, was measured by reading
optical absorbance at 490 nm. The COX-2 level was
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determined from a standard curve generated for each set
of samples assayed.
The VEGF content of tissue cytosolic samples was
quantified by an enzyme-linked immunosorbent assay
(Quantikine Human VEGF Immunoassay, R&D Systems,
Minneapolis, MN). The assay employs the quantitative sandwich
enzyme immunoassay technique using recombinant human
VEGF and antibodies raised against the recombinant protein.
Details of the assay have been described elsewhere[21,30]. The
assay exhibits no significant cross-reactivity with other
angiogenic factors. All samples were assayed in duplicate.
Statistical analysis
Continuous variables were expressed as median and range,
and compared between groups using the Mann-Whitney
U test. Categorical variables were compared between groups
using the 2 test with Yates’ correction (or the Fisher’s exact
test where appropriate). Correlation of continuous variables
was examined using the Spearman correlation test (r).
Survival was computed using the Kaplan-Meier method
and compared between groups using the log-rank test. The
prognostic influence of  tumor COX-2 levels and tumor
pathological features on survival was studied by a multivariate
analysis using the Cox regression model. All statistical analyses
were performed using a statistical software (SPSS/PC, SPSS
Inc., Chicago, IL). A P value <0.05 was considered statistically
significant.
RESULTS
Among the 100 patients with HCC studied, there were 82
men and 18 women, and the median age was 55 years (range
16-79 years). Eighty-five patients (85%) tested positive for
HBV surface antigen, 4 (4%) tested positive for anti-HCV
antibody, and the other patients were seronegative for both
HBV and HCV. Forty-seven patients (47%) had associated
cirrhosis according to histological examination. The median
size of the tumors was 5.7 cm (range 1.5-20.0 cm).
Immunohistochemical study of COX-2 expression in tumors
and adjacent noncancerous liver tissues
Immunohistochemical staining of  COX-2 in the tumors
showed that COX-2 was expressed predominantly in the
cytoplasm of tumor cells (Figure 1A). Of the tumor specimens,
56 cases were classified as positive and 44 cases as negative
for COX-2 by immunostaining.
In the adjacent noncancerous liver tissues, COX-2 was
expressed to a variable extent, predominantly in the
hepatocytes (Figure 1B). Positive staining was also observed
in endothelial cells and stromal cells in both tumor and
adjacent noncancerous liver tissues. Of the noncancerous
liver tissue specimens, 49 cases were classified as positive
and 51 cases as negative for COX-2. In contrast, immunostaining
for COX-2 was negative in all 10 specimens of  normal
liver obtained from living liver donors.
Tumor and noncancerous liver cytosolic COX-2 levels and
correlation with cytosolic VEGF levels
The median cytosolic COX-2 concentration in the tumors
was 0.350 ng/mg total protein (range 0.044-1.971 ng/mg
total protein), which was not significantly different from
that of the corresponding adjacent noncancerous livers
(median 0.378 ng/mg total protein, range 0.053-1.885 ng/mg
total protein; P = 0.216). In contrast, the cytosolic VEGF
concentration in the adjacent noncancerous livers (median
22.8 pg/mg total protein, 12.7-37.6 ng/mg total protein)
was significantly lower than that in the tumors (median
46.3 pg/mg total protein, 23.0-143.6 ng/mg total protein;
P<0.001). Positive correlation was observed between tumor
COX-2 and VEGF levels (r = 0.469, P<0.001), and between
noncancerous liver COX-2 and VEGF levels (r = 0.230,
P = 0.021). A detailed study of cytosolic VEGF concentration
in tumor and noncancerous adjacent tissues and their
association with clinicopathological parameters has been
reported in a previous publication from our group[30].
Relationship between tumor cytosolic COX-2 levels and
clinicopathological features
Table 1 shows the relationship between tumor cytosolic
COX-2 levels and tumor pathological features. There was a
significant association between high tumor COX-2 levels
and the presence of multiple tumors (P = 0.027), venous
invasion (P = 0.030), microscopic satellite lesions (P = 0.037),
and advanced pTNM stage (P = 0.008). Figure 2 shows the
boxplots of  tumor COX-2 levels in early stage (I/II) vs advanced
stage (III/IVA) HCCs. There was no significant association
between tumor COX-2 levels and tumor grade or tumor size
(≤ or >5 cm in diameter). When correlated as continuous
variables, there was no significant relationship between tumor
COX-2 levels and tumor size (r = 0.040, P = 0.694). Tumor
COX-2 levels did not have a significant correlation with
serum alpha fetoprotein levels either (r = 0.046, P = 0.654).
Figure 1  Immunohistochemical staining for COX-2. A: a section of a
HCC showing expression of the COX-2 protein (brownish staining)
predominantly in the tumor cells; B: a section of nontumorous liver
tissue showing expression of the COX-2 protein in the hepatocytes
(magnification 10×).
A
B
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Relationship between noncancerous liver cytosolic COX-2
levels and clinicopathological features
There was no significant difference in the noncancerous
liver cytosolic COX-2 levels between patients tested positive
for HBV and those tested negative for HBV (0.370 [0.065-
1.885] vs 0.387 [0.053-1.128] ng/mg total protein, P = 0.527),
nor was there any significant difference in the noncancerous
liver cytosolic COX-2 levels between patients with cirrhosis
and those without cirrhosis (0.401 [0.070-1.885] vs 0.370
[0.053-1.128] ng/mg total protein, P = 0.386).
There was no significant correlation between cytosolic
COX-2 levels in the noncancerous liver tissues and serum
alanine aminotransferase levels (r = 0.108, P = 0.283), aspartate
aminotransferase levels (r = 0.004, P = 0.972), albumin
levels (r = -0.124, P = 0.218) or bilirubin levels (r = 0.030,
P = 0.765). No significant difference was observed in the
cytosolic COX-2 levels in the noncancerous livers between
those patients with active inflammation (n = 48) and those
without active inflammation in the livers (n = 52) (0.405
[0.065-1.885] vs 0.368 [0.053-1.130] ng/mg total protein,
P = 0.831).
Relationship between tumor COX-2 levels and prognosis
The 100 patients were stratified into those with a low
tumor cytosolic COX-2 level (less than the median level
0.350 ng/mg total protein) and those with a high tumor
cytosolic COX-2 level (greater than 0.350 ng/mg total
protein). Patients with a high tumor cytosolic COX-2 level
had significantly worse long-term survival compared with
those with a low tumor cytosolic COX-2 level (P = 0.027,
Figure 3). There was no significant association between
adjacent noncancerous liver cytosolic COX-2 levels (stratified
by the median value) and patient survival (P = 0.116).
Of  the seven tumor pathological features listed in Table 1,
presence of venous invasion (P = 0.005) and advanced
pTNM stage (P<0.001) had significant adverse prognostic
influence on survival by univariate analysis. When these
two factors were entered into a Cox multivariate analysis
together with tumor COX-2 levels, only advanced pTNM
stage was an independent prognostic factor (risk ratio
2.138, 95% confidence interval 1.309-3.492, P = 0.002).
DISCUSSION
Since HCC is one of the most vascular human malignancies,
angiogenesis plays an important role in this tumor. However,
relatively little is known of the role of various angiogenic
factors in HCC compared with other common human
cancers[31]. Several recent reports on COX-2 expression in other
cancers show that COX-2 can induce angiogenesis and is
related to tumor growth, invasion, and metastasis[7,11-14,32,33].
Although COX-2 is also known to have an antiapoptotic
effect on tumor cells[34], its angiogenic property is believed
to play a major role in its relationship with cancer growth
and progression[35]. A few studies have evaluated the
expression of  COX-2 in HCC[22,23,25,26,34]. However, unlike
the studies in other cancers, these studies in HCC have not
demonstrated a significant correlation between COX-2
expression and the pathological features of cancer invasion or
progression. Instead, some of  these studies suggested that COX-
2 may be involved in the early stage of hepatocarcinogenesis
because of  the finding of  higher COX-2 expression in well-
differentiated HCC[22,23,34]. Other studies suggested that
Figure 2 Boxplots showing significantly higher tumor COX-2 levels
in patients with advanced tumor stage (III and IVA) compared with
those with early tumor stage (I or II) (P = 0.008). The upper and lower
horizontal lines of the box indicate the 25th and 75th percentiles,
respectively. The lines within the box indicate the median values.
The upper and lower horizontal bars indicate data within 1.5 times
the interquartile range.
Figure 3  Cumulative survival curves of patients with high tumor
cytosolic COX-2 (>0.350 ng/mg total protein) and low tumor cytosolic
COX-2 (<0.350 ng/mg total protein) levels (P = 0.027).
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Table 1  Relationship between COX-2 levels in tumor cytosol and
pathological features of HCC
Tumor characteristics             Tumor COX-2 P
            cytosolic level
     (ng/mg total protein)
Tumor size: ≤5 cm (n = 44)        0.385 (0.084–1.971)       0.567
        >5 cm (n = 56)        0.350 (0.044–1.690)
Tumor number: solitary (n = 72)        0.305 (0.044–1.971)       0.027
             multiple (n = 28)        0.423 (0.086–1.690)
Tumor grade: well-differentiated (n = 36)        0.376 (0.084–1.539)       0.799
    Moderately- or poorly-differentiated (n = 64) 1    0.349 (0.044–1.971)
Venous invasion: absent (n = 60)        0.295 (0.083–1.325)       0.030
               present (n = 40)        0.410 ( 0.044–1.971)
Microscopic satellite lesions: absent (n = 78)        0.310 (0.093–1.971)       0.037
present (n = 22)        0.495 (0.044–1.690)
Tumor encapsulation: absent (n = 71)        0.351 (0.044–1.971)       0.587
      present (n = 29)        0.372 (0.084–1.325)
pTNM stage: I and II (n = 50)        0.286 (0.083–1.325)       0.008
III and IVA (n = 50)        0.410 (0.044–1.971)
1Includes 60 moderately-differentiated and 4 poorly-differentiated HCCs.
COX-2 may be involved in the inflammatory activity in the
adjacent noncancerous liver[23,24]. A correlation between
COX-2 expression and tumor angiogenesis in HCC has been
demonstrated in two previous studies[25,26], but these studies
did not demonstrate any correlation between COX-2 expression
and pathological features of tumor invasiveness.
To our knowledge, this is the first study that demonstrated
a significant correlation between increased tumor COX-2
expression and tumor invasiveness in HCC. Previous
studies that failed to show a significant relationship between
COX-2 expression and features of  HCC invasiveness used
immunohistochemical study alone in the evaluation of
COX-2 expression, which is a crude semiquantitative
method[22,23,25,34]. This study shows that high levels of tumor
cytosolic COX-2 measured by an EIA were significantly
associated with tumor multiplicity, presence of venous
invasion, presence of microscopic satellite lesions and
advanced tumor stage. These were all features indicative
of tumor invasiveness and progression. The absence of
correlation between tumor cytosolic COX-2 levels and tumor
size suggests that COX-2 level is not simply related to tumor
growth in size but is specifically related to tumor invasiveness.
This is the only study thus far that has quantitatively
measured the tissue cytosolic COX-2 protein levels in HCC.
Previous studies that employed a similar method to quantify
VEGF levels in other cancers have shown that this method
provided a reliable quantitative evaluation of tumor expression
of the angiogenic factor, which correlated well with tumor
invasiveness and progression[36,37].
The difference in the results between this study and
previous studies by Japanese groups may also be partly
ascribed to different patient populations, as the current study
population consists of predominantly (85%) patients with
HCC related to HBV infection, whereas the majority of
patients in the Japanese studies had HCV-related HCC.
Differences in the clinicopathological characteristics of
HCCs related to HBV infection and those related to HCV
infection have been well documented[38,39]. It is possible that
COX-2 may have a different role in HCCs caused by
different viral etiologies. Such a speculation is supported by
a recent study that demonstrated induction of  COX-2
expression by HBV X protein, which is often the only viral
protein expressed by transformed hepatocytes in HCC
caused by HBV infection[40]. The study showed that HBV
X protein could induce HCC cell invasion through the COX-
2 pathway, thus contributing to the metastatic spreading
and recurrence of  HBV-related HCC.
The present study also demonstrated a significant
correlation between tumor cytosolic COX-2 and VEGF
levels in HCC. This finding is in agreement with those of
studies in other human cancers[12,14]. VEGF is a highly specific
angiogenic factor, and high tumor or serum VEGF levels
have been shown to be related to venous invasion, intrahepatic
metastasis and advanced tumor stage in patients with HCC
in our previous studies[20,21]. Several investigators have
demonstrated that COX-2-derived prostaglandins facilitate
angiogenesis by upregulation of VEGF expression, and the
increased levels of  VEGF can be reversed by using COX-2
inhibitor such as Celecoxib, suggesting that COX-2 regulates
VEGF expression and angiogenesis in cancer[14,41,42]. The
current study suggests that COX-2 enhances the invasiveness
of HCC probably through its angiogenic effect via the VEGF
pathway. Venous invasion and advanced tumor stage are
important risk factors of tumor recurrence after resection
of  HCC[43]. The association between high COX-2 levels and
venous invasion as well as advanced tumor stage explains
its negative impact on long-term patient survival.
In this study, COX-2 expression was also detected to a
variable degree in the noncancerous liver tissues, which were
affected by cirrhosis or chronic hepatitis in most cases. In
contrast, COX-2 was not expressed in normal liver tissue
taken from living liver donors. In addition to its effect on
angiogenesis, COX-2 is a mediator of  chronic inflammation.
Upregulated expression of  COX-2 in the adjacent noncancerous
livers has been demonstrated in previous studies of  HCV-
related HCC[23,24]. Other studies have also shown that there
is little or no expression of  COX-2 in normal liver without
HBV or HCV infection[23,44]. However, while previous studies
in patients with HCV infection showed a significant
relationship between COX-2 expression and inflammatory
activity in the noncancerous livers[23,24], our data did not reveal
a significant association between cytosolic COX-2 levels
and the inflammatory activity in the adjacent noncancerous
livers in HBV-related HCCs. There was no significant
correlation between COX-2 expression in the noncancerous
liver tissues and serum transaminase levels, which indirectly
reflect hepatitis activity in the liver. Our results are in
agreement with a recent study that reported elevated COX-
2 expression in chronic hepatitis in patients with HBV
infection, but the COX-2 expression level did not correlate
with inflammatory activity in that study either[44].
The role of  COX-2 in the noncancerous liver of  HCC
patients remains to be clarified. A recent study suggested
that COX-2 may be involved in liver fibrosis[45]. Another
study showed that VEGF expression is increased in cirrhosis
and may mediate angiogenesis in cirrhotic liver in HCC
patients[46]. The present study demonstrated for the first time
a significant correlation between COX-2 and VEGF in the
noncancerous liver tissues, suggesting that COX-2 may also
be involved in the angiogenesis in chronic liver disease
through the VEGF pathway. COX-2 may play a specific
role in the chronic liver disease induced by HBV. HBV X
protein has recently been found to induce VEGF expression
and angiogenesis in HBV-infected noncancerous liver, which
may contribute to hepatocarcinogenesis[47]. HBV X protein
has also been shown to induce COX-2 expression[40]. Together
with our finding of  positive correlation of  COX-2 and VEGF
levels in the noncancerous liver, it is reasonable to speculate
a role of  COX-2 in the angiogenesis and hepatocarcinogenesis
induced by HBV X protein. However, the relationship
between COX-2 and HBV X protein in HBV-infected liver
needs clarification with further studies.
The elucidation of  the significance of  COX-2 in the
invasiveness and progression of HCC is of potential clinical
importance as it provides insight into the feasibility of
using COX-2 inhibitors as an anticancer therapy for HCC.
Nonsteroidal anti inflammatory drugs have been shown to
exhibit antineoplastic activity in a number of malignancies
because of  their ability to inhibit COX-2[6,8]. Recently, specific
COX-2 inhibitors have been developed and shown to possess
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antitumor activity through inhibition of angiogenesis[48].
COX-2 is an important therapeutic target in tumor angiogenesis,
and COX-2 inhibitors are being intensely investigated as a
novel anticancer therapy[8,9]. A recent experimental study
has demonstrated that COX-2 inhibitors could inhibit
angiogenesis and growth of prostate cancer[49]. It has been
suggested that COX-2 inhibitors may be an effective strategy
of chemoprevention of HCC[50]. The data from this study
provide the rationale for future studies to evaluate the use
of  COX-2 inhibitors not only for chemoprevention but also
as a therapy for established invasive HCC. Currently, we
are conducting a study on the effect of  a COX-2 inhibitor,
Celecoxib, on human HCC xenotransplant in a nude mice
model. Our preliminary unpublished data show that
Celecoxib could inhibit the growth of HCC xenotransplant.
COX-2 inhibition may be useful in the treatment of
inoperable HCC, either as a monotherapy or in combination
with other therapies, and it may also be useful as an adjuvant
therapy to prevent recurrence after resection of HCC. This
is an attractive approach worthy of further investigation in
view of the current lack of effective chemotherapy for
HCC[43].
In conclusion, this study shows that tumor cytosolic
COX-2 levels correlate with VEGF levels and pathological
features of tumor invasiveness in HCC. The possible
involvement of  COX-2 in the angiogenesis and invasiveness
of HCC represents a novel finding that not only provides
clues for a better understanding of  the tumor biology of
HCC, but also unveils a potential novel target for therapy
against this aggressive malignancy.
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